Kronox Lab Sciences Promoters Sell 64.26% Stake to Indo Borax for ₹2463 Crore
Promoters of Kronox Lab Sciences Limited have agreed to sell 64.26% stake to Indo Borax & Chemicals Limited for approximately ₹2,463 crore. The deal involves 2,38,44,000 equity shares at ₹103.22 per share. A mandatory tender offer to public shareholders will follow. This transaction leads to a change in promoters and control.
A change in promoters and the sale of over 64% of the company's equity will fundamentally alter the management, control, and strategic direction of Kronox Lab Sciences Limited, impacting all stakeholders.
The transaction signifies a change in ownership with a new promoter taking over, which can bring fresh capital and strategic direction, potentially benefiting the company's future growth.
Kronox Lab Sciences Limited has announced a significant change in its ownership structure. The company's promoters, Mr. Ketan Vinodchandra Ramani, Mr. Pritesh Vinodchandra Ramani, and Mr. Jogindersingh Gianchand Jaswal, have entered into a Share Purchase Agreement (SPA) dated August 20, 2026, with Indo Borax & Chemicals Limited (Acquirer) and Zenrock Chemicals Private Limited (ZCPL).
Under this SPA Transaction, the Sellers will transfer an aggregate of 2,38,44,000 equity shares, representing approximately 64.26% of the company's total paid-up equity share capital, to the Acquirer. The per share price for this sale is ₹103.22. Consequently, the Acquirer, along with ZCPL (as persons acting in concert), will be required to make a mandatory tender offer to the public shareholders of Kronox Lab Sciences Limited, as per SEBI regulations.
Upon completion of the transaction, the Acquirer will become the promoter, and ZCPL will be classified as the promoter group, gaining control of the company. The existing promoters will cease to be in control and will be re-classified into the 'public' category. The transaction is subject to fulfillment of certain conditions precedent. The Sellers will also enter into a consultancy agreement with the company and resign from the Board, while the Acquirer will appoint three nominee directors. The total value of the transaction is approximately ₹2,463 crore (23,844,000 shares * ₹103.22 per share).
What to do with a filing like this
Kronox Lab Sciences Limited filed this with the NSE as a statutory disclosure, categorised under substantial acquisition of shares and takeovers. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Kronox Lab Sciences Limited. Read the original for the full detail.